Skip to Main Content

Good day, everyone! Nick Florko here filling in for the great Ed Silverman. I’m here in the beautiful Pine Tree State but today’s stimulation is, well, underwhelming. We are sipping a can of coffee because the other option was the motel’s continental breakfast. Here’s hoping your choices are better. Now for today’s news. …

A federal judge is pushing back his expected ruling on Purdue Pharma’s bankruptcy reorganization plan, Reuters reports. The judge, Robert Drain, was originally expected to rule on the plan by Friday but now anticipates making a ruling next Wednesday. The plan has garnered outsized attention in recent days because it would shield members of the wealthy Sackler family that own Purdue from future lawsuits regarding their role in the opioid crisis, in addition to massively restructuring the company.


European regulators have cleared Biomarin’s (BMRN) drug for one of the most common types of dwarfism, achondroplasia, Reuters tells us. In the U.S., the Food and Drug Administration is expected to decide on the drug by November 20.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Create a display name to comment

This name will appear with your comment

There was an error saving your display name. Please check and try again.